BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

BioNTech (BNTX) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and ...

An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (NASDAQ: BNTX). Investors were concerned about the latest top-level ...

Phase 1/2a trial of BNT324/DB-1311 in solid tumors showed a 32.4% unconfirmed objective response rate and 82.4% disease control rate. BNT324/DB-1311 showed a manageable safety profile across all ...

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where BioNTech SE (NASDAQ:BNTX) stands against other ...

I rate BioNTech SE a hold due to volatile financial performance, weak growth, and premium valuation. The company's financials are heavily reliant on COVID-19 vaccines, with declining demand impacting ...